血管性血友病:未来治疗方向展望
本文为综述,指出VWD临床管理约30年基本未变,仍以VWF浓缩物、去氨加压素和抗纤溶药为主;生活质量研究显示患者负担高于预期,尤其女性。文章提出基因治疗、蛋白及抗体策略等未来方向。
要点
- VWD管理约30年无实质变化,以VWF浓缩物、去氨加压素、抗纤溶药为主。
- 生活质量研究显示VWD患者负担高于预期,女性尤为明显。
- 未来方向包括基因治疗、提高FVIII水平的蛋白策略及抗体干预VWF降解或水平。
核心结论
- 当前VWD治疗虽被认为有效,但生活质量研究提示患者负担仍高于预期,存在创新空间。
- VWD治疗创新复杂,需考虑疾病异质性和VWF多功能性。
研究设计与样本
- 本文为观点/综述类文章,未报告系统检索范围或样本量。
主要发现
- VWD临床表现异质性高,诊断和管理复杂。
- 过去约30年VWD临床管理基本未变,与血友病A持续创新形成对比。
- 生活质量研究一致显示VWD患者负担高于预期,女性尤为明显。
临床怎么用
- 当前实践仍以VWF浓缩物、去氨加压素和抗纤溶药控制出血。
- 未来可能探索基因治疗、蛋白策略及抗体策略等创新方向。
局限性
- 本文为观点文章,未提供具体研究数据或系统评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
von Willebrand disease (VWD) is characterized by its heterogeneous clinical manifestation, which complicates its diagnosis and management. The clinical management of VWD has remained essentially unchanged over the last 30 years or so, using von Willebrand factor (VWF) concentrates, desmopressin, and anti-fibrinolytic agents as main tools to control bleeding. This is in contrast to hemophilia A, for which a continuous innovative path has led to novel treatment modalities. Despite current VWD management being considered effective, quality-of-life studies consistently reveal a higher than anticipated burden of VWD on patients, which is particularly true for women. Apparently, despite our perceived notion of current therapeutic efficiency, there is space for innovation with the goal of reaching superior efficacy. Developing innovative treatments for VWD is complex, especially given the heterogeneity of the disease and the multifunctional nature of VWF. In this perspective article, we describe several potential strategies that could provide the basis for future VWD treatments. These include genetic approaches, such as gene therapy using dual-vector adenoassociated virus and transcriptional silencing of mutant alleles. Furthermore, protein-based approaches to increase factor FVIII levels in VWD-type 3 or 2N patients are discussed. Finally, antibody-based options to interfere with VWF degradation (for congenital VWD-type 2A or acquired von Willebrand syndrome-type 2A) or increase endogenous VWF levels (for VWD-type 1) are presented. By highlighting these potential strategies, we hope to initiate an innovative path, which ultimately would allow us to better serve VWD patients and their specific needs.
引用
- Denis CV, Susen S, Lenting PJ, et al. von Willebrand disease: what does the future hold? Blood. 2021. PMID: 33662989. doi:10.1182/blood.2020008501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。